C ardiovascular disease (CVD) remains an enormous burden on healthcare resources in the United States. According to the American Heart Association (AHA), 1 in every 3 deaths is attributed to CVD, and expenses related to CVD represent 17% of overall national health expenditures. 1 Overall, $320 billion are attributed annually to direct costs of, and loss of productivity due to, CVD. By 2030, almost half of the US population is expected to be diagnosed with CVD, and consequently CVD costs are projected to triple. 1 Established cardiovascular risk factors (CRFs)-most of which can be modified, treated, or controlled-are the most important drivers of death and disability. 1-9 Because of their Background-The American Heart Association's 2020 Strategic Goals emphasize the value of optimizing risk factor status to reduce the burden of morbidity and mortality. In this study, we aimed to quantify the overall and marginal impact of favorable cardiovascular risk factor (CRF) profile on healthcare expenditure and resource utilization in the United States among those with and without cardiovascular disease (CVD). Methods and Results-The study population was derived from the 2012 Medical Expenditure Panel Survey (MEPS). Direct and indirect costs were calculated for all-cause healthcare resource utilization. Variables of interest included CVD diagnoses (coronary artery disease, stroke, peripheral artery disease, dysrhythmias, or heart failure), ascertained by International Classification of Diseases, Ninth Edition, Clinical Modification codes, and CRF profile (hypertension, diabetes mellitus, hypercholesterolemia, smoking, physical activity, and obesity). Two-part econometric models were used to study expenditure data. The final study sample consisted of 15 651 MEPS participants (58.5±12 years, 54% female). Overall, 5921 (37.8%) had optimal, 7002 (44.7%) had average, and 2728 (17.4%) had poor CRF profile, translating to 54.2, 64.1, and 24.9 million adults in United States, respectively. Significantly lower health expenditures were noted with favorable CRF profile across CVD status. Among study participants with established CVD, overall healthcare expenditures with optimal and average CRF profile were $5946 and $3731 less compared with those with poor CRF profile. The respective differences were $4031 and $2560 in those without CVD. Conclusions-Favorable CRF profile is associated with significantly lower medical expenditure and healthcare utilization among individuals with and without established CVD. (Circ Cardiovasc Qual Outcomes. 2016;9:143-153.
significant relevance, the AHA's 2020 Strategic Impact Goals emphasize the importance of optimizing CRF profile as part of a national goal, to reduce CVD morbidity, mortality, and economic burden. 10 Although there are few reports highlighting the economic burden of some individual modifiable risk factors, [11] [12] [13] [14] [15] the impact of global CRF on healthcare costs, and resource utilization across the spectrum of CVD is not well described.
Given this gap in knowledge, the goal of this study was to detail the healthcare costs across varying modifiable CRF profiles in a nationally representative population. We hypothesized that favorable CRF profile will be associated with significantly lower direct healthcare expenditure and resource utilization irrespective of CVD status.
Methods

Study Design and Sampling
This was a retrospective study that used data from the Medical Expenditure Panel Survey (MEPS), 2012. The MEPS, led by the Agency for Healthcare Research and Quality, is a set of large scale, national surveys about individuals and families, their medical providers and their employers. The Household Component of the MEPS collects data about health services used, their frequency and cost, charges, source of payment, income, employment, as well as ample data on insurance used by, and available to, US workers. 16 The MEPS respondents are enrolled for 2 years of data collection, with a new panel beginning each year. The sampling frame for the MEPS-Household Component is drawn from respondents to the National Health Interview Survey and the design of the MEPS-Household Component survey includes sampling weights, stratification, and clustering. The MEPS sampling weights incorporate adjustment for the complex sample design and reflect survey nonresponse and population totals from the Current Population Survey. 16 Different files from the Household Component were used for this project: full-year consolidated data files, medical conditions files, and event files. The full-year consolidated data files include most demographics on a person-level, whereas the medical conditions files include each diagnosis a person has, which after being transcribed verbatim at each survey, are translated into International Classification of Diseases, Ninth Edition, Clinical Modification by professional coders. Finally, each event file denotes healthcare resource utilization per person, including hospitalizations, emergency department (ED) visits, and outpatient clinic/office-based visits. All files were linked together to determine accurate results for each individual. Because MEPS is comprised of publically available de-identified data files, it was exempt from Institutional Review Board review. 17 
Participants
The initial sample consisted of 38 974 surveyed individuals. We limited our study population to noninstitutionalized US adults ≥40 years of age (excluding 11 688 individuals <40 years of age) because of the low prevalence of established CVD among adults aged 18 to 39 years. Individuals with body mass index <18.5 kg/m 2 (11 635) were also excluded from the sample given that they often represent a sicker patient population.
Study Variables
CVD and Average Modifiable Cardiovascular Risk Factor Status
Individuals in the study sample who had a diagnosis of coronary artery disease, stroke, heart failure, dysrhythmias, or peripheral artery disease (ascertained by ICD-9-CM codes: 410, 413, 414, 433 -437, 427, 428, 440, 443 and 447, respectively) were classified as having diagnosed CVD. CRFs were ascertained using self-reported questionnaires in the Household Component survey, where individuals with the presence of ≥1 of: hypertension, diabetes mellitus, hypercholesterolemia, lack of physical exercise (defined as not participating in moderate-vigorous physical activity, ≥30 minutes, ≥ 5×/wk), smoking, or obesity (body mass index ≥30 kg/m 2 , a constructed variable using self-reported weight and height) were included. On the basis of the presence of these individual risk factors, survey participants were profiled as poor (≥4 CV risk factors), average (3-2 CV risk factors) or optimal (0-1 CV risk factors).
Expenditures and Resource Utilization
Total annual direct medical expenditures were calculated for each person. Data for this variable included expenditures from all payer groups and out-of-pocket spending, including information from hospitalizations, prescribed medications, outpatient visits (hospital outpatient visits and office-based visits), emergency department visits, and other expenditures (dental visits, vision aid, home healthcare, and other medical supplies). In a similar fashion, resource utilization analysis assessed the total number of outpatient and ED visits, number of hospitalizations and number of prescription medications' purchases/refills each surveyed individual incurred. In a subanalysis, we also estimated indirect healthcare expenditures. For 2012, the mean hourly wage in the US was $22.01, according to the Bureau of Labor Statistics. 18 Each workday was considered to be composed of 6 hours (conservative measurement). From 2 separate variables representing each individual's work absenteeism, indirect costs (ie, loss of productivity) were calculated by multiplying the number of days missed from work from either illness or injury and any additional days in bed, by the national average daily wage, $132.06 ($22.01×6 hours), 19 further stratifying by CRF profile and CVD status.
WHAT IS KNOWN
• Favorable cardiovascular risk factor profile emphasized by American Heart Association 2020 Strategic Impact Goals is established to be associated with lower risk of cardiovascular disease morbidity and mortality. • The impact of favorable cardiovascular risk factor status on healthcare costs and resource utilization across the spectrum of cardiovascular disease status is not well described. 
WHAT THE STUDY ADDS
Statistical Analysis
For comparison of demographic characteristics in our sample, χ 2 tests were performed. 20 Because of the right skewedness of expenditures data (ie, most expenditures are seen in only a small proportion of the population), 2-part models were used to study expenditures. 21 Two-part models are often used to model healthcare expenditures and are the product of: (1) the probability that any given individual had any expenditures and (2) their mean expenditures. 22 The first part of the model consists on a probabilistic regression model (probit), which estimates the probability of zero versus positive expenditures. Contingent on having a positive annual healthcare expenditure, a generalized linear model (glm) with γ distribution and a logarithmic-link function estimates the average expenditure per capita 22, 23 ; we determined the distribution of the glm using the modified Park Test. 24 For resource utilization, unadjusted and adjusted logistic regression models were used. Unadjusted means and proportions were calculated, adjusting for the survey design and sampling weight. For all statistical analyses, P<0.05 was considered statistically significant. All analyses were carried out using Stata, version 13.1 (StataCorp, LP, College Station, TX). Total and marginal expenditures were estimated using the margins command after the 2-part models. 22 All analyses took into consideration the MEPS complex survey design.
Results
Population Characteristics
Demographic characteristics for the study population are shown in Table 1 . The total study sample consisted of 15 651 participants ≥40 years of age (58.5±12 years, 54% female), which translates to ≈143.4 million US adults. Overall, 1872 (13.3%) had a CVD diagnosis, representing 19 million of the noninstitutionalized adult population in the United States The most frequent diagnoses among those with CVD were coronary artery disease (65.5%), dysrhythmias (24.6%), and stroke (18.3%). Those with CVD were more likely to be older, male, and have poor CRF profile as well as higher burden of comorbid conditions (Table 1 ).
In the total study population, 5921 (37.8%) had optimal, 7002 (44.7%) had average, and 2728 (17.4%) had poor CRF profile, translating to 54.2, 64.1, and 24.9 million individuals in the United States, respectively. As shown in Table 2 , irrespective of the presence or the absence of CVD, those with poor CRF profile were more likely to be older, report lower socioeconomic and education status, and a higher prevalence of comorbid conditions.
Healthcare Expenditures
Adjusted and unadjusted average per-capita healthcare expenditures, by CRF profile and CVD status are shown in Table 3 . Presence of CVD was associated with higher overall healthcare expenditures compared with those without diagnosis of CVD across the entire spectrum of CRF profile. Individuals with CVD and poor CRF profile had a mean annual expenditure of $16 171 compared with $8874 among those with an optimal CRF profile (Table 3, model 1). Conversely, among those without CVD, the mean annual total healthcare expenditure of participants with poor CRF profile was $7851 compared with $3463 among those with an optimal CRF profile. Further adjustment for covariates including demographics, insurance, and socioeconomic status, as well comorbid conditions, the relationship remained robust, those with average and optimal CRF profile when compared with poor CRF, had $3732 (95% confidence interval [CI], 2093-5501) and $5946 (95% CI, 3595-8335) lower total healthcare expenditure in those with established CVD (Table 3, model 3) . Similarly, lower marginal healthcare expenditures were noted in those without any CVD ($2559 with average, $4030 with optimal), respectively. On examination of the impact of the presence of individual CRF, the highest marginal expenditures were noted with lack of moderate-vigorous physical activity ($2853), diabetes mellitus ($2599), and hypertension ($2423) among those with CVD, whereas among those without CVD, highest marginal total healthcare expenditures were noted with the presence of diabetes mellitus ($3211) and hypertension ($1253) ( Figure 1) . Figure 2 details levels of specific expenditures (prescription drugs, hospitalizations, ED visits, office-based visits, and other) according to CRF profile and CVD status. Adjusting for covariates including demographics, insurance, and socioeconomic status, as well comorbid conditions, individuals with CVD and a poor CRF profile spent an annual average of $4879 on hospitalizations and $4590 on prescription medications compared with $2453 and $1928 for those with optimal CRF profile, respectively. Among those without CVD, those with poor CRF profile spent an average of $2192 and $2414 for hospitalizations and prescription medications, respectively. Overall, those without CVD an optimal CRF profile had the lowest expenditures, with an average of $1060 on hospitalizations, $770 on prescription medications, and $1483 on outpatient visits. Similar trends were noted among those <65 and ≥65 years of age, respectively ( Supplementary  Figure 1 ).
Indirect Costs
An overview of indirect costs is provided in Table 4 . Overall, average annual indirect costs accounting for the actual loss of productivity from work caused by disability (injury, illness, or any additional bed days) was significantly lower among those with optimal CRF ($345) and average CRF ($479) when compared with those with poor CRF status ($498). After controlling for demographics, insurance, socioeconomic status, and comorbid conditions, annual indirect costs were highest for those with CVD and a poor CRF profile ($1145) and the lowest indirect costs observed for those without CVD and optimal CRF profile ($293). Table 5 summarizes healthcare utilization rates across CRF profile categories and CVD status. Overall, favorable CRF profile was associated with significantly less use of healthcare resources. Among survey participants with CVD, those with optimal versus poor CRF profile were less likely to have an ED visit (21.4% versus 31.3%) or any hospitalization (18.8% versus 29%). The lowest rate of ED visits (7.6%) and hospitalizations (3.4%) was noted in those with optimal CRF profile without diagnosis of CVD (Table 5 ). After adjusting for key covariates, among individuals without CVD, those with optimal CRF profile had 61% lower odds of being hospitalized (odds ratio, 0.39 [95% CI, 0.29-0.52]), 58% lower odds of having an ED visit (odds ratio, 0.42 [95% CI, 0.34-0.52]), 72% lower odds of outpatient visit (odds ratio, 0.28 [95% CI, 0.22-0.35]), and 90% lower odds of purchasing/refilling a prescription medication (odds ratio, 0.10 [95% CI, 0.08-0.13]) when compared with those with poor CRF profile.
Healthcare Resource Utilization
Discussion
With nearly 800 000 deaths per year, CVD remains the leading cause of mortality in the United States 1 It has been well documented that the higher CVD incidence and subsequent mortality is driven by prevalent traditional risk factors. As a result, the AHA emphasized its "Strategic Impact Goals for 2020" to optimize CRF profile associated with CVD. Several studies have clearly established that favorable CRF profile is associated with a significant reduction in the risk of CVD events and mortality in a dose-response fashion. 12, [25] [26] [27] [28] [29] Although to date multiple reports have attempted to estimate the incremental healthcare expenditures with individual CRFs, 12-14,26,30-33 the potential economic impact of favorable Our study findings are consistent with previous reports, and the results of this study add to the current literature by demonstrating significantly lower overall healthcare expenditure and resource utilization among those with favorable CRF profile across the spectrum of CVD status in a US national representative cohort. The average healthcare annual expenditure was highest for the group with both CVD and poor CRF profile ($14 157) and lowest for those without CVD and optimal CRF profile ($3998). For most groups, medications cost was the largest component of total cost, followed by hospitalizations, ED, and outpatient clinic visits costs. Although it is well established that the majority of healthcare costs increase occur in the elderly, our findings also highlight significant benefit of favorable CRF profile even among <65 years.
An additional significant finding of our study is that although among those without established CVD, average medical expenditure comparing optimal versus poor CRF status was nearly 50% lower, it is important to realize that overall costs and resource utilization were significantly lower compared with individuals with favorable CRF and (Table 3 ; Figure 2 ). With a mean annual cost differential of almost two-and-half-fold higher with CVD across each CRF strata, the value of primary prevention among those without established CVD cannot be understated. Kahn et al 27 demonstrated that fully applied prevention activities can potentially increase annual healthcare -$3,000.00 -$2,000.00 -$1,000.00 $0.00 $1,000.00 $2,000.00 $3,000.00 $4,000.00 $5,000.00 -$3,000.00 -$2,000.00 -$1,000.00 $0.00 $1,000.00 $2,000.00 $3,000.00 $4,000.00 $5,000.00
Total
CVD
Non-CVD
-$3,000.00 -$2,000.00 -$1,000.00 $0.00 $1,000.00 $2,000.00 $3,000.00 $4,000.00 $5,000.00 costs by ≈$1700 per person; but our analysis suggest that these increased costs can be potentially offset by avoiding the incremental expenditures associated with managing those who progress to develop overt CVD (ie, transition from primary to secondary prevention). Our findings provide robust economic insights on practical policies addressing future healthcare costs of modifiable CRFs. With implementation of the Affordable Care Act, a much steeper drop in uninsured individuals is expected, resulting in a shift toward greater healthcare government spending, from the actual 17.4% to 19.6% of the gross domestic product. 34 Aging is the single most important risk factor for CVD and associated costs, which is unfortunately nonmodifiable. 25 As a result, priority must be given to programs with potential to provide the largest return on investment, particularly when resources may be scarce because of rising healthcare costs and slower economic growth. The AHA's Strategic Impact Goals' emphasis on optimizing cardiovascular health provides a balanced approach between primordial prevention efforts at individual and population/societal levels. An example being the Million Hearts Initiative, to limit or eliminate tobacco use, encouraging active lifestyle with a focus on obesity, which will synergistically influence on reducing risk of additional comorbidities, such as hypertension, hyperlipidemia, and diabetes mellitus, allowing for further inroads to control the growing cost of CVD. 35, 36 Results from our analysis support the focus on prevention, as well as expansion on screening and counseling for modifiable CRFs, which are already included as a key element of the Affordable Care Act, 37 and can play a critical role in containing healthcare costs. The focus on modifiable CRF with other policies in a comprehensive prevention package has the potential to significantly bend the curve of rising healthcare costs. Equally important, however, will be the determination of how and which preventive efforts can actually halt the transition to CVD. For instance, the Look AHEAD study, although thorough, did not find a decrease in the risk for major CVD. 38 Others, like Espeland et al, 26 discuss how specific intensive lifestyle interventions are most beneficial for certain at-risk groups, such as obese and overweight diabetics before CVD appears, but not afterward. However, many preventive programs do have significant cost savings, but are often not reimbursed, or not paid for in the current health system. 39 This study is not without limitations. First, the prevalence of CVD in this study is lower than previous national estimates (13% versus 36%). 1 This is because the diagnosis of CVD in our study did not consider hypertension, and instead was included in the spectrum of modifiable CRF profile assessment. Second, the variable for physical activity was taken from the self-reported questionnaires of the MEPS survey (moderate-vigorous activity, ≥30 minutes, ≥5 d/wk), and it may be a higher standard of physical activity than the average individual in the United States. Third, as CVD and modifiable CRF were self-reported, underestimation of the true national prevalence is likely, as has been previously described, especially with chronic conditions. 40 As a result, the estimates in our study are likely to be conservative. Because of lack of information on dietary habits, we were not able to account for this important modifiable risk factor. In addition, due to reliance on self-reported risk factors and lack of information on blood pressure, total cholesterol and fasting glucose levels, we were unable to estimate the prevalence of AHA's defined ideal CV health status in our study. Fourth, other analyses have found that MEPS data tend to underestimate total medical expenditures. [41] [42] [43] This limitation would lead to a likely underestimation of the actual cost associated with increasing burden of modifiable CRF as well as estimating savings from primordial prevention strategies. Fifth, the results of this study are generalizable to the noninstitutionalized adult US population, but may not be relevant for other populations. Finally, there is a risk of residual confounding. Although we comprehensively controlled for most important observed contributing variables, there may be unobserved characteristics that affect the outcomes studied. In conclusion, we found significantly lower healthcare expenditure and resource utilization among patients with favorable cardiovascular risk profile. These results emphasize and provide robust estimates for potential healthcare savings with nationwide policies focusing on preventing and managing modifiable risk factors, irrespective of underlying CVD status. 
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